Kaplan–Meier estimates of the cumulative Disease Free Interval (DFI) were significantly different in favor of patients with non-methylated BRMS1 promoter (Figure 3A; Ρ = 0.042), as we have previously reported for a different cohort of breast cancer patients (27). This evidence concerns the gene BRMS1 and breast carcinoma.